Biocon secures clearer pathway for breast cancer biosimilar after patent settlement with Genentech

Biocon has secured a clearer pathway to launch its breast cancer biosimilar Pebrilzo (pertuzumab) in major regulated markets after reaching a global patent settlement with Genentech.

Detected & updated continuously · Source: Nebula